Masoabi Sefojane: The Cost of a 35-Year Diagnosis Delay
Masoabi Sefojane, Geographic Expansion Lead, Africa and Asia Pacific at MicroHealth , shared a post on LinkedIn:
“The Cost of a 35-Year Diagnosis Delay
A child waits 35 years for diagnosis.
Not weeks.
Not months.
Three and a half decades.
During that time: untreated bleeds.
Preventable joint damage.
Chronic pain.
Opportunities gone.
The World Bleeding Disorders Registry tracked data from 40 countries.
The pattern is unmistakable: diagnosis in low-middle-income countries lags up to 4 decades behind high-income countries.
But statistics don’t capture this cost.
Without early prophylaxis, haemophilic arthropathy develops by age 20.
Permanent joint damage.
The 3-hour journeys to the nearest centre.
The surgeries that follow.
The professional opportunities lost to disability.
By age 30-40, this damage is irreversible.
In South Africa alone, treating a single severe haemophilia patient on demand costs over R1.29 million per year. Prophylaxis costs R949,000. That R342,000 annual difference per patient compounds across a lifetime, before a single surgery, physiotherapy session, or lost wage is counted. The modelling doesn’t even include the cost of long-term complications, disability, or mortality.
In sub-Saharan Africa, 36.5% of patients over 20 have musculoskeletal damage. 39% have no professional activities.
Call it what it is: late diagnosis creates preventable disability.
Here’s the cruel part: we know how to prevent this.
Primary prophylaxis before age 3 prevents joint damage almost entirely.
So the gap isn’t clinical knowledge.
The gap is systems.
We have knowledge.
We don’t have coordination.
If we could prevent 95% of this damage with early diagnosis, why are our systems only finding 37% of patients?”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics